A 40-year-old woman is diagnosed with a 1.5 cm invasive ductal carcinoma of the breast. Immunohistochemistry shows ER-negative, PR-negative, and HER2-positive status. Which targeted therapy is indicated as part of her adjuvant treatment?
- A Trastuzumab ✓
- B Tamoxifen
- C Anastrozole
- D Palbociclib
Correct answer: A. Trastuzumab
Explanation
Trastuzumab is a monoclonal antibody against HER2 and is the standard targeted therapy for HER2-positive breast cancer. Tamoxifen and anastrozole are hormonal therapies used for ER-positive cancers, while palbociclib is a CDK4/6 inhibitor used in metastatic ER-positive disease.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.